sur Theranexus (EPA:ALTHX)
THX Pharma: Allinvest Securities Recommends Buying the Stock
On June 16, 2026, Allinvest Securities announced that its stock had been covered. A research note highlights a 226% upside potential for the stock, with a price target of €10.40, compared to €3.205 on June 15.
This coverage highlights THX Pharma's strategic transformation, which has refocused on rare diseases with Batten-1 and TX01. Partnerships with Exeltis and Biocodex have strengthened its credibility and financial position, marking a significant change in its risk profile.
With this coverage, THX Pharma aims to increase its stock market visibility and reaffirm its commitment to transparent communication. It is now being followed by two financial analysis firms.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Theranexus